Stable Isotopic Analysis of Porcine, Bovine, and Ovine Heparins

JOHN P. JASPER,¹ FUMING ZHANG,² RUSSELL B. POE,³ ROBERT J. LINHARDT^{2,4}

¹Molecular Isotope Technologies LLC, Niantic, Connecticut 06357

²Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180

³Birch Biopharmaceutical Consultants LLC, Groton Connecticut 06340

⁴Departments of Chemistry and Chemical, Biology, Biology, Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180

Received 8 June 2014; revised 12 July 2014; accepted 29 July 2014

Published online 3 September 2014 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.24134

ABSTRACT: The assessment of provenance of heparin is becoming a major concern for the pharmaceutical industry and its regulatory bodies. Batch-specific [carbon (δ^{13} C), nitrogen (δ^{15} N), oxygen (δ^{18} O), sulfur (δ^{34} S), and hydrogen (δ D)] stable isotopic compositions of five different animal-derived heparins were performed. Measurements readily allowed their differentiation into groups and/or subgroups based on their isotopic provenance. Principle component analysis showed that a bivariate plot of δ^{13} C and δ^{18} O is the best single, bivariate plot that results in the maximum discrimination ability when only two stable isotopes are used to describe the variation in the data set. Stable isotopic analyses revealed that (1) stable isotope measurements on these highly sulfated polysaccharide (molecular weight ~15 kDa) natural products ("biologics") were feasible; (2) in bivariate plots, the δ^{13} C versus δ^{18} O plot reveals a well-defined relationship for source differentiation based on the hydrologic environmental isotopes of water (D/H and 18 O/I⁶O); and (4) the δ^{15} N versus δ^{18} O and δ^{34} S versus δ^{18} O relationships are both very similar, possibly reflecting the food sources used by the different heparin producers. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:457–463, 2015 **Keywords:** heparin; stable isotopic analysis; animal sourced; principle component analysis; mass spectrometry; analysis

INTRODUCTION

Heparin is a linear sulfated polysaccharide consisting of repeating $1 \rightarrow 4$ -glycosidically linked hexuronic acid and glucosamine residues (Fig. 1).¹ Heparin is biosynthesized in the Golgi of mast cells of humans,² other vertebrates,³ and invertebrates.⁴ Pharmaceutical heparin is primarily produced from the intestines and lungs of food animals, primarily pig, bovine cattle, and sheep. It is a critically important anticoagulant drug used in cardiopulmonary bypass, hemodialysis, in the treatment of coagulation abnormalities, as coating materials for implantable devices, and in the preparation of low molecular weight heparins.⁵ Heparin, while commanding a multibillion dollar worldwide market, has a fragile supply chain that was jeopardized in the past by fears of prion (i.e., bovine spongiform encephalopathy and scrapies) and viral impurities,⁶ was briefly interrupted in 2007–2008 during a contamination crisis,⁷ and has been adversely impacted by the recent appearance of the porcine epidemic diarrhea virus.8

Although only porcine intestinal heparin is currently used in the United States, bovine lung and intestinal heparins^{9,10} have been used in South America and in the Middle East, and

Journal of Pharmaceutical Sciences, Vol. 104, 457-463 (2015)

ovine intestinal and porcine lung heparins have been used in Asia. Heparins derived from different organisms and tissues display different physical-chemical properties (i.e., molecular weight properties, disaccharide composition, and antithrombin III pentasaccharide binding sites (Fig. 1)),¹¹⁻¹⁴ different in vitro anticoagulant activities,^{12,15-17} different pharmacology (i.e., in vivo efficacy, pharmacodynamics, and side effects, etc.),^{18–23} and potentially carry different impurities (i.e., polysaccharides, peptides, virus, prions, etc.).^{11,24} Regulatory concerns about the substitution of one heparin for another or the blending of heparins coming from two different organisms or tissues have lead to the development of assays to assess the provenance of a given heparin.^{6,24–29} Crude porcine heparins (the unbleached intermediate used to prepare heparin active pharmaceutical ingredient (API)) are currently assessed by quantitative PCR qPCR, which can sensitively detect the presence of ruminant DNA, suggesting blending of porcine heparin with ovine or bovine heparin.^{6,25–27} When using this qPCR method, heparinase is required to degrade the heparin present in the sample to ensure accurate detection, as the heparin-mediated inhibition of PCR was previously described.³⁰ One-dimensional and two-dimensional nuclear magnetic resonance (NMR) spectroscopy of porcine heparin API can detect the presence of bovine heparin or ovine heparin but only when present in relatively large amounts ($\sim 25\%$).¹¹ Multivariate analysis of NMR data allows for the detection of smaller levels of bovine heparin API blended into porcine heparin API.¹⁶ The current study examines a novel method relying on natural-abundance stable isotope analysis³¹ to examine the provenance of heparin products. Stable isotope studies on heparin API require little sample preparation or pretreatment

Abbreviations used: EA/IRMS, elemental analyzer/isotope ratio mass spectrometer; TCEA, thermal conversion/elemental analyzer; API, active pharmaceutical ingredient; NMR, nuclear magnetic resonance.

Correspondence to: John P. Jasper (Telephone: +860-739-1926; Fax: +860-739-3250; E-mail: JPJasper@NaturesFingerprint.com); Robert J. Linhardt (Telephone: +518-276-3404; Fax: +518-276-3405; E-mail: linhar@rpi.edu)

This article contains supplementary material available from the authors upon request or via the Internet at http://onlinelibrary.wiley.com/.

^{© 2014} Wiley Periodicals, Inc. and the American Pharmacists Association



 $a + d \sim 20$, b = 0 or 1, c ~ 8 for MW_W average 20,000 X = SO₃⁻, H; Y= SO₃⁻, COCH₃, H

Figure 1. Typical structure of heparins (viz., relative elemental composition of $\rm C_{12}H_{15}NO_{19}S_3Na_4;$ molecular weight: 10–15 kDa). The structural variability of their antithrombin III (AT) binding sites has been previously determined. 11

Jasper et al., JOURNAL OF PHARMACEUTICAL SCIENCES 104:457-463, 2015

and can be rapidly and routinely performed on multiple samples.

The stable isotopic compositions of selected light elements (e.g., C, N, O, S, H) are very useful in determining the natural origin of materials^{32,33} as well as the "manufacturer or batch" origin of the products and materials manufactured from them.^{34,35} Stable carbon isotopes have been particularly useful in differentiating large classes of plant organic matter based on their photosynthetic pathways: for example, C3terrigenous versus C3-algal sources, where C3 plants fractionate to a greater degree (using Rubisco) than do C4 plants (using ribulose-1,5-bisphosphate (RUBP) carboxylase). In addition, the stable isotopic composition of nitrogen (δ^{15} N) is highly variable in nature through a number of pathways for inorganic as well as organic species.³³ Furthermore, the stable isotopic composition of sulfur $(\delta^{34}S)$ has been demonstrated to have very high dynamic ranges (observed ranges/ 1σ SD > 200) in pharmaceutical studies and typically serves as an excellent tracer of isotopic provenance.36

Stable isotopic characterization of individual batches of industrial products ("Nature's Fingerprint[®]") through their patented synthetic pathways ("IsoPedigreeSM") provides a highly specific means to identify product batches and to protect chemical process patents.³⁵ In the period between the expiration dates of composition-of-matter patents and of their paired process patents, stable isotopic analyses permit a novel and efficient means by which to protect the intellectual property of biopharmaceutical/pharmaceutical products^{35,37} through identifying isotopic differences.³⁸

The current study explores the use of isotopic quantification on a limited suite of animal-derived heparin products. In addition to affording information of the organism and/or tissue source of a heparin, these data might even provide a "location fingerprint" and a "manufacturer's fingerprint" of heparin production.

MATERIALS AND METHODS

Materials

Five samples of animal-derived heparin APIs (heparins #1–5) were examined (Table 1). These samples consisted of porcine intestinal heparin sourced from the United States (Celsus Laboratories, Cincinnati, Ohio, 202 U/mg), China (Dongying Pharmaceutical Inc., Shangdong, China, 200 U/mg), and Spain (Bioiberica SA, Barcelona, Spain, 203 U/mg), bovine lung heparin (150 U/mg) and ovine intestinal heparin (182 U/mg) purchased from Sigma Chemical Corporation (St. Louis, Missouri). The heparins were all sodium salts having approximate elemental compositions of $C_{12}H_{15}NO_{19}S_3Na_4$ with molecular weights of ~15 kDa. Detailed chemical structural and biological analysis were performed on all the five heparin APIs.^{11,39} These previous NMR studies, disaccharide analyses, molecular weight analyses, and biological analyses demonstrated that all of these heparin samples were of high purity.

Stable Isotopic Analyses

Five stable isotope ratios (δ^{13} C, δ^{15} N, δ^{34} S, δ^{18} O, and δ D) were measured on each of the five heparin API samples with singlicate analysis for heparins #2–5 and in one triplicate analysis for heparin #1 to assess analytical precision.^{39,40} Thus, a total of 35 stable isotopic measurements of these heparin (i.e., 5

Sample Number/Name	Source	δ ¹³ C (%)	PSE ¹³ C (%)	$\begin{matrix} \delta^{15}N \\ (\%) \end{matrix}$	PSE ¹⁵ N (%)	δ ¹⁸ O (%)	PSE ¹⁸ O (%)	δD (%)	PSE D (%)	$\delta^{34}S$ (%)	PSE ³⁴ S (%)
1/Porcine heparin	USA	-14.15	0.03	-2.80	0.03	4.30	0.05	33.8	0.6	-5.35	0.02
1/Porcine heparin	USA	-14.26	0.03	-2.75	0.03	4.14	0.05	33.6	0.6	-5.34	0.02
2/Bovine heparin	Unknown	-21.08	0.06	-2.49	0.06	0.90	0.13	16.3	1.1	-3.57	0.04
3/Ovine heparin	Unknown	-28.27	0.06	-0.43	0.06	5.50	0.13	80.8	1.1	6.30	0.04
4/Porcine heparin	China	-16.55	0.06	-2.68	0.06	3.82	0.13	22.7	1.1	-2.24	0.04
5/Porcine heparin	Spain	-21.55	0.06	-2.37	0.06	4.37	0.13	23.7	1.1	-3.60	0.04

Table 1. Stable Isotopic Compositions of Heparin Samples

batches \times 5 isotope ratios plus replicates) presented in Table 1 were performed in this study.

Carbon and Nitrogen Isotope Analyses

Individual solid samples of ~1.0 mg for δ^{13} C and ~3.7 mg for δ^{15} N analysis were weighed and placed into tin boats that were crimped tightly around the analyte. Carbon (δ^{13} C) and nitrogen (δ^{15} N) isotopic analyses were performed with a Carlo Erba 1108 Elemental Analyzer interfaced using a Conflo III interface to a Thermo Scientific Delta V isotope ratio mass spectrometer (EA/IRMS). The EA operated with an oxidation furnace temperature of 1020°C, reduction furnace temperature of 650°C, and a packed-column temperature of 70°C. All isotopic standards employed here are reported relative to the standards of the International Atomic Energy Agency (IAEA). δ^{13} C values are reported relative to the international Vienna Peedee Belemnite (VPDB) standard. δ^{15} N values are reported relative to the international air standard.

Sulfur Isotope (δ³⁴S) Analyses

For δ^{34} S analysis, individual solid samples containing 150– 300 µg of sulfur within the sample along with approximately 10 times the total sample weight of WO₃ as an oxidant were weighed into tin boats that were crimped tightly around those materials. Isotopic analysis was performed with an Elementar Vario EL III Elemental Analyzer interfaced via a Finnigan MAT ConFlo III to a Thermo Delta V Advantage Isotope Ratio Mass Spectrometer (EA/IRMS). The EA operated with an oxidation furnace temperature of 1150°C followed by a reduction furnace set at 850°C. Gas flow rates were 200 mL/min for helium and 1 mL/min for oxygen, which is dosed for 90 s directly to the combustion zone. The δ^{34} S values are reported in percentage relative to the international standard Vienna Canyon Diablo Troilite (VCDT) iron meteorite.

Oxygen Isotope (δ^{18} O) Analyses

Individual samples of ~0.2 mg were weighed and placed into silver boats, which were then crimped tightly around the analyte. Triplicate oxygen (δ^{18} O) stable isotopic analyses of one of the five samples were performed on a Finnigan Thermal Conversion/Elemental Analyzer (TCEA) interfaced to Finnigan Delta V Plus isotope ratio mass spectrometer (IRMS, thus a TCEA/IRMS). Analogous to a standard Elemental Analyzer/Isotope Ratio Mass Spectrometer (EAMS),⁴¹ the TCEA functions with samples sequentially delivered into a furnace and the effluent gases analyzed by an online IRMS, but with pyrolysis (instead of oxidative combustion as in the EA/IRMS) performed at 1400°C. The TCEA thermally converts analytes to CO rather than combustion into H₂O and CO₂ as in the EAMS. The analyte gas, CO, is chromatographically separated on a packed column at 85° C. The mass spectrometer measures ¹⁸O in the form of CO.

Hydrogen (δD) Isotopic Analyses

In general, hydrogen that is not bound to carbon in a molecule, readily exchanges with other hydrogen atoms present in ambient moisture (i.e., H_2O). This exchange even happens at room temperature and is difficult to control reliably. In order to use δD values to uniquely identify a compound, the exchangeable hydrogen portions must be accounted for or controlled in some way. Samples were weighed and dried under vacuum for 1 week to remove ambient moisture. The dried samples were then immediately transferred to a Costech Zero Blank autosampler and evacuated to remove moisture.

Samples were weighed and wrapped inside individual $3.5 \text{ mm} \times 5 \text{ mm}$ silver "boats." All materials were then dried under vacuum in the presence of a desiccant to remove moisture. Samples were then loaded into the autosampler of a Finnigan MAT, Thermal Conversion Elemental Analyzer (TCEA). Along with each batch of samples, we also included several reference standards, such as a polyethylene standard that has no exchangeable hydrogen and is therefore unaffected by ambient moisture. Samples were then reduced at 1400°C in the presence of glassy carbon. The resulting hydrogen was then separated from other gases using a gas chromatograph and passed into an IRMS for isotopic analysis to obtain the δD values.

Units of Stable Isotopic Measurement

Carbon (and all other) isotopic results are expressed in δ values (% = parts per thousand differences from international standards) defined as:

$$\delta^{13}C(\%_0) = ([(R_{\rm smpl})/(R_{\rm std})] - 1) \times (1000)$$

where R_{sample} = the ¹³C/¹²C ratio of the sample material and R_{std} = the ¹³C/¹²C ratio of an IAEA standard (known as "VPDB" whose ¹³C/¹²C ratio has been defined as the official zero point of the carbon isotopic scale). ¹⁵N/¹⁴N values are given relative to the international air standard. ³⁴S/³²S values are given relative to the IAEA VCDT standard. ¹⁸O/¹⁶O and D/H values are given relative to the IAEA Vienna Standard Mean Ocean Water standard.

Estimates of Uncertainty

The uncertainty (or precision) of the isotopic measurements in this study was estimated from the pooled SD of recent studies. In those cases, the pooled SD of raw data were estimated to derive a representative SD from the whole raw data set in



Figure 2. Principle component analysis of the stable isotopic composition of heparin samples: biplot of scores and loadings.

which small numbers of replicates (viz., n = 1-3) were pooled to generate a representative SD of the whole sample suite.³⁸ Characteristic one sigma (1 σ) SD for the isotope values used in this study were δ^{13} C ($\pm 0.06\%$), δ^{15} N ($\pm 0.06\%$), δ^{18} O ($\pm 0.08\%$), δ D ($\pm 1.1\%$), and δ^{34} S ($\pm 0.04\%$), as shown in Table 1.

RESULTS AND DISCUSSION

The ¹³C, ¹⁸O, ¹⁵N, ³⁴S, and D Analyses of Heparin Samples

The results of stable isotopic analyses ($\delta^{13}C$, $\delta^{18}O$, $\delta^{15}N$, $\delta^{34}S$, and δD) of the five heparin samples given are presented in Table 1 and Figures 3–6.

In the following sections, the δ^{13} C, δ^{18} O, δ^{15} N, δ^{34} S, and δ D data from Table 1 are displayed in bivariate plots, and in principle component analysis (PCA) analysis their relationships are discussed and assessed.

PCA of the Stable Isotopic Composition of Heparin Samples

The data set contains results from five stable isotopes and five samples. One sample (porcine heparin #1) was tested in three replicates to estimate the intrasample variation in the data set. Prior to performing PCA, the triplicates of the porcine heparin sample #1 were averaged and the average was used in the analysis so that each sample would have equal weight. The data were then autoscaled by mean centering followed by dividing by the SD. Two principle components were empirically selected: principle component 1 accounted for 80% of the variance of the data set followed by principle component 2, which accounted for 16% of the variance in the data set so that these two principle components accounted for 96% of the total variance of the data set.

The principle component scores and loadings are jointly displayed in the biplot in Figure 2. From the loadings, the correlation between stable isotopes can be deduced as well as the ability of the stable isotope to differentiate between the heparin samples. The loadings show a strong correlation between δ^{15} N, δ^{34} S, and δ D and that these three isotopes are strongly, inversely



Figure 3. An isotopic bivariate $(\delta^{13}C-\delta^{18}O)$ plot of the three (ovine, bovine, porcine) heparin samples. Most important graph for source differentiation: separates USA-porcine heparin from non-USA heparin.

correlated with δ^{13} C. The isotope, δ^{18} O, is the most highly differentiated variable showing less correlation to the other isotopes and also being the only isotope that allows differentiation of porcine heparin samples from heparin from other sources. The sample scores indicate (1) that the porcine samples are relatively high in δ^{13} C, (2) that bovine heparin is relatively low in δ^{18} O, and (3) that ovine heparin is relatively high in δ^{15} N, δ^{34} S, and δ D. Shannon entropy criterion⁴² is related to the amount of information and confirms that a bivariate plot of δ^{13} C and δ^{18} O is the best single, bivariate plot, which results in the minimum of $-\log|R|$, where |R| is the determinant of the correlation coefficient matrix when only two stable isotopes are used to describe the variation in the data set.

Bivariate Isotope Plots of the Stable Isotopic Composition of Heparin Samples

Four bivariate plots of the stable isotopic results collected from the heparin samples are given in Figures 3–6 to show the interrelationship of the isotopic results and their groupings.

Although there are 11 such plots, PCA shows that the four paired $\delta X-\delta^{18}O$ values, shown in Figures 3–6, are probably the most useful (where $\delta X=\delta^{13}C,\,\delta D,\,\delta^{15}N,\,\delta^{34}S)$). The seven other optional plots complete the set of 11 (see Supplementary Figs. S1–S7).

Four bivariate graphs of the paired $\delta X - \delta^{18}O$ values of the heparin samples are shown in Figures 3–6. Significantly, the graphs as a group and the data in Table 1 show high dynamic ranges from the isotopic values (from 43 for $\delta^{15}N$ to 308 for $\delta^{34}S$ where dynamic range = observed range/1 σ SD), and therefore a high specificity (1.1 × 10¹⁰ = product of the five dynamic ranges) in differentiating this sample suite of biologic pharmaceutical materials (see Supplementary Table S1).

As indicated by the PCA, the $\delta^{13}C-\delta^{18}O$ graph (Fig. 3) shows a significant differentiation of the three types of heparin (porcine, ovine, and bovine) as well as a distinct differentiation of the three sources of porcine heparin (USA, China, and



Figure 4. An isotopic bivariate $(\delta D - \delta^{18}O)$ plot of the three (ovine, bovine, porcine) heparin samples. Maximum resolving power for the three types of heparin.



Figure 5. An isotopic bivariate ($\delta^{15}N-\delta^{18}O$) plot of the three (ovine, bovine, porcine) heparin samples.

Spain). Furthermore, PCA indicates that the $\delta D - \delta^{18}O$ graph (Fig. 4) differentiates the three types of heparin with maximum resolving power. Finally, PCA analysis indicates a close similarity of $\delta^{15}N$ and $\delta^{34}S$. This similarity is manifested in the $\delta^{15}N - \delta^{18}O$ and $\delta^{34}S - \delta^{18}O$ graphs (Figs. 5 and 6, respectively), which also strongly resolve the three types of heparin (also see Supplementary Figures S1–S7).

This study only demonstrates differences in the stable isotope distribution of a small number of heparin APIs and does not provide any data supporting the underlying mechanism for these differences. It is, however, possible to speculate on the cause of such differences in isotopic distribution. The major animal sources of heparin API, pig, sheep, and bovine cattle, have different diets, digestive systems, and gut (or lung) flora. Pigs are naturally omnivorous but are commercially raised on grains and legumes and have a gut flora similar to that of hu-



Figure 6. An isotopic bivariate $(\delta^{34}S - \delta^{18}O)$ plot of the three (ovine, bovine, porcine) heparin samples.

mans and other monogastrics. In contrast, sheep and cattle are grazing ruminants eating a diet rich in fiber cellulosics with a complex microbial flora consisting of bacteria, methanogens, yeast, molds, and protozoans. Studies using stable isotopes have shown differences in carbon isotope fractionation by ruminants and nonruminants⁴³ as well as isotope incorporation differences between different ruminants, including ovine and bovine species.44 The diet of animals can also impact C and N isotope ratios⁴⁵ as can differences in their gut microbiome.⁴⁶ The triplicate analysis of a single porcine intestinal heparin (heparin #1, hogs raised in the United States) shows very little analytical variation in the measurement of stable isotope distributions. The analyses of porcine intestinal heparins show similar stable isotope distribution with some differences based on the geographic area where the animals were raised. These differences might be attributable to different strains of pigs, different diets, different environmental factors, different seasons of animal harvesting, different microbiomes, or different factory processing of these heparins.^{5,47} Differences were observed between heparins derived from ovine intestine and bovine lung (as compared with porcine intestinal heparin) but no firm conclusions can be drawn from these differences because of the limited number of samples studied.

CONCLUSIONS

Thirty-five measurements of the δ^{13} C, δ^{15} N, δ^{34} S, δ^{18} O, and δ D isotope ratios of five samples of animal-derived heparins and presumably other biologic molecules readily allow differentiation of the samples into groups and/or subgroups based on their stable isotopic provenance.

In particular, the stable isotopic analyses revealed that (1) stable isotopic measurements of biologic molecules, such as heparin (molecular weight ~10–15 kDa), were feasible; (2) in bivariate plots, the δ^{13} C versus δ^{18} O plot reveals a well-defined relationship for source differentiation, separating

USA-porcine heparin from non-USA heparin; (3) the δD versus $\delta^{18}O$ plot reveals the most well-defined relationship for source differentiation based on the hydrologic environmental isotopes of water (D/H and ${}^{18}O/{}^{16}O$); and (4) the $\delta^{15}N$ versus $\delta^{18}O$ and $\delta^{34}S$ versus $\delta^{18}O$ relationships are both very similar, suggesting that the food sources used for animals by different heparin producers may play a role.

Heparin products that are also chemically (i.e., Arixtra) or chemoenzymatically (i.e., bioengineered heparin)⁴⁷ synthesized. Although these heparins are not natural products, their manufacturing provenance might also be monitored using stable isotope methods.^{35,37,38} Such monitoring might also be useful in preventing the introduction of counterfeit synthetic heparins onto the world market.

ACKNOWLEDGMENTS

This work was supported by grants (HL101721 and HL096972) from the National Institutes of Health. We thank Mark Swift and Peter Farina for their early guidance in the stable isotopic analysis of biologics.

REFERENCES

1. Linhardt RJ. 2003. Heparin: Structure and activity. J Med Chem 46:2551–2554.

2. Linhardt RJ, Ampofo SA, Fareed J, Hoppensteadt D, Mulliken JB, Folkman J. 1992. Isolation and characterization of human heparin. Biochemistry 31:12441–12445.

3. Loganathan D, Wang HM, Mallis LM, Linhardt RJ. 1990. Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry 29:4362–4368.

4. Luppi E, Cesaretti M, Volpi N. 2005. Purification and characterization of heparin from the Italian clam *Callista chione*. Biomacromolecules 6:1672–1678.

5. Linhardt RJ, Gunay NS. 1999. Production and chemical processing of low molecular weight heparins. Sem Thromb Hemostas 25:5– 16.

6. Concannon SP, Wimberley PB, Workman WE. 2011. A quantitative PCR method to quantify ruminant DNA in porcine crude heparin. Anal Bioanal Chem 399:757–762.

7. Liu H, Zhang Z, Linhardt, RJ. 2009. Lessons learned from the contamination of heparin. Nat Prod Rep 26:313–321.

8. Wang L, Byrum B, Zhang Y. 2014. New variant of porcine epidemic diarrhea virus, United States. Emerg Infect Dis 20:917–919.

9. Junqueira DR, Viana TG, Peixoto ER, Barros FC, Carvalho MD, Perini E. 2011. Heparin pharmacovigilance in Brazil. Rev Assoc Med Bras 57:322–326.

10. Gomes WJ, Braile DM. 2009. The troubled heparin issue in the Brazilian market and the search for solutions. Rev Bras Cir Cardiovasc 24:3–4.

11. Fu L, Li G, Yang B, Onishi A, Li L, Sun P, Zhang F, Linhardt RJ. 2013. Structural characterization of pharmaceutical heparins prepared from different animal tissues. J Pharm Sci 102:1447–1457.

12. Tovar AM, Capillé NV, Santos GR, Vairo BC, Oliveira SN, Fonseca RJ, Mourão PA. 2012. Heparin from bovine intestinal mucosa: Glycans with multiple sulfation patterns and anticoagulant effects. Thromb Haemost 107:903–915.

13. Mascellani G, Liverani L, Bianchini P. 1996. Analysis of heparin origin by HPLC quantitation of disaccharide components. Farmaco 51:247–254.

14. Casu B, Guerrini M, Naggi A, Torri G, De-Ambrosi L, Boveri G, Gonella S, Ronzoni G. 1995. Differentiation of beef and pig mucosal heparins by NMR spectroscopy. Thromb Haemost 74:1205.

15. Tovar AM, Teixeira LA, Rembold SM, Jr Leite M, Lugon JR, Mourão PA. 2013. Bovine and porcine heparins: Different drugs with similar effects on human haemodialysis. BMC Res Notes 6:230.

16. Gotti R, Parma B, Spelta F, Liverani L. 2013. Affinity capillary electrophoresis in binding study of antithrombin to heparin from different sources. Talanta 105:366–371.

17. Aquino RS, Pereira MS, Vairo BC, Cinelli LP, Santos GR, Fonseca RJ, Mourão PA. 2010. Heparins from porcine and bovine intestinal mucosa: Are they similar drugs? Thromb Haemost 103:1005–1015.

18. Warkentin TE. 2003. Pork or beef? Ann Thorac Surg 75:15–16.

19. Schmitt BP, Adelman B. 1993. Heparin-associated thrombocytopenia: A critical review and pooled analysis. Am J Med Sci 305:208–215.
20. Boldt J, Zickmann B, Ballesteros M, Scholz D, Dapper F, Hempelmann G. 1991. Does the preparation of heparin influence anticoagulation during cardiopulmonary bypass? J Cardiothorac Vasc Anesth 5:449–453.

21. Bailey RT Jr, Ursick JA, Heim KL, Hilleman DE, Reich JW. 1986. Heparin-associated thrombocytopenia: A prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin. Drug Intell Clin Pharm 20:374–378.

22. Silverglade A. 1975. Biological equivalence of beef lung and hog musosal heparins. Curr Ther Res Clin Exp 18:91–103.

23. Harada A, Tatsuno K, Kikuchi T, Takahashi Y, Sai S, Murakami Y, Takada K. 1990. Use of bovine lung heparin to obviate anaphylactic shock caused by porcine gut heparin. Ann Thorac Surg 49:826–827.

24. Rivera V, Levieux A, Levieux D. 2002. Immunochemical characterisation of species-specific antigens in bovine crude heparin. J Pharm Biomed Anal 29:431–441.

25. Huang Q, Xu T, Wang GY, Huang JF, Xia H, Yin R, Tang A, Fu WL. 2012. Species-specific identification of ruminant components contaminating industrial crude porcine heparin using real-time fluorescent qualitative and quantitative PCR. Anal Bioanal Chem 402:1625–1634.

26. Houiste C, Auguste C, Macrez C, Dereux S, Derouet A, Anger P. 2009. Quantitative PCR and disaccharide profiling to characterize the animal origin of low-molecular-weight heparins. Clin Appl Thromb Hemost 15:50–58.

27. Huang Q, Yao CY, Chen B, Wang F, Huang JF, Zhang X, Fu WL. 2006. Species-specific identification by inhibitor-controlled PCR of ruminant components contaminating industrial crude porcine heparin. Mol Cell Probe 20:250–258.

28. Ruiz-Calero V, Saurina J, Galceran MT, Hernández-Cassou S, Puignou L. 2002. Estimation of the composition of heparin mixtures from various origins using proton nuclear magnetic resonance and multivariate calibration methods. Anal Bioanal Chem 373:259–265.

29. Levieux A, Rivera V, Levieux D. 2002. Immunochemical control of the species origin of porcine crude heparin and detection of ovine and caprine materials. J Pharm Biomed Anal 27:305–313.

30. Satsangi J, Jewell DP, Welsh K, Bunce M, Bell JI. 1994. Effect of heparin on polymerase chain reaction. Lancet 343:1509–1510.

31. Carter J, Meirer-Augenstein W. 2012. Stable isotope analysis of drugs. In Wiley's encyclopedia of forensic science; Jamieson A, Moenssens A, Eds. Wiley-Blackwell, pp 1–9.

32. Smith BN, Epstein S. 1971. Two categories of ${}^{13}C/{}^{12}C$ ratios for higher plants. Plant Physiol 47:380–384.

33. Fogel ML. 2010. Variations in abundances of nitrogen isotopes in nature. In Encyclopedia of mass spectrometry; Beauchemin D, Matthews DE, Eds. Vol. 5. Oxford, UK: Elsevier, pp 842–851.

34. Jasper JP. 2004. Pharmaceutical security: Using stable isotopes to authenticate pharmaceutical materials. Tablets Capsules 2:37–42.

35. Jasper JP, Weaner LE, Hayes JM. 2007. Process patent protection: Characterizing synthetic pathways by stable-isotopic measurements. Pharm Technol 31:68–73.

36. Jasper JP. 1999. The increasing use of stable isotopes in the pharmaceutical industry. Pharm Technol 23:106–114.

37. Jasper JP, Pavane M, Eyler D, Sharma I, Lee A. 2012. Process patent protection: Protecting intellectual property via natural-abundance stable isotopes. Am Intel Prpty Law Assoc.

38. Jasper JP, Lyon RC, Weaner LE. 2005. Stable isotopes provide a new PAT [process analytical technology] tool. Pharm Mfg 4:28–33.

39. Zhang F, Yang B, Ly M, Solakyildirim K, Xiao Z, Wang Z, Chang Y, Dordick JS, Linhardt RJ. 2011. Chemical structure characterization of commercial heparin from different commercial sources. Anal Bioanal Chem 401:2793–2803.

40. Jasper JP. 2001. Quantitative estimates of precision for molecular isotopic measurements. Rap Commun Mass Spectrom 15:1554–1557.

41. Habfast K. 1997. Advanced isotope ratio mass spectrometry I: Magnetic isotope ratio mass spectrometers. In Modern isotope ratio mass spectrometry; Platzner IT, Ed. New York: John Wiley and Sons, Ltd., pp 11–82.

42. Jin R, Chen W, Sudjianto A. 2005. An efficient algorithm for constructing optimal design of computer experiments. J Stat Plan Infer 120:268–287.

43. Cerling TE, Harris JM. 1999. Carbon isotope fractionation between diet and bioapatite in ungulate mammals and implications for ecological and paleoecological studies. Oecologia 120:347–363.

44. Evershed RP, Dudd SN, Copley MS, Mutherjee A. 2002. Identification of animal fats via compound specific δ^{13} C values of individual fatty acids: Assessments of results for reference fats and lipid extracts of archaeological pottery vessels. Doc Praeh 29:73–96.

45. Kuitems M, van Kolfschoten T, van der Plicht J. 2012. Elevated δ^{15} N values in mammoths: A comparison with modern elephants. Archaeol Anthropol Sci. doi: 10.1007/s12520-012-0095-2.

46. Harris CI, Fuller MF, Torrallardona D. 2003. Pigs' gastrointestinal microflora provide them with essential amino acids. J Nutr 133:1127–1131.

47. Bhaskar U, Sterner E, Hickey AM, Onishi A, Zhang F, Dordick JS, Linhardt RJ. 2012. Engineering of routes to heparin and related polysaccharides. Appl Microbiol Biotechnol 93:1–16.